Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Court documents outline J&J’s involvement in a dermatology experiment 50 years ago on incarcerated individuals, most of whom were African American.
The single-shot chikungunya vaccine was shown to be safe and effective against mosquito-transmitted chikungunya disease in a published analysis of Phase III results.
On Monday, Moderna announced its initiative that promises to advance those 15 programs into the clinic by 2025.
From research to sales and marketing, the pharma industry has a wide range of employment opportunities to accommodate those looking for a chance to work in the field.
Kurma Partners earned €160 million in the first closing of its Growth Opportunities fund, and Atlas Venture raked in its largest round of funding yet to invest in new biotech firms.
Voyager has partnered with Novartis for the latter to use the gene therapy company’s capsid discovery platform to create new treatments for three undisclosed CNS targets.
Potential outbreaks in Ukraine, genetic variants cause worsened symptoms, new long-term effects discovered and Florida political representatives advise against vaccines for kids.
Bristol Myers Squibb’s moneymaker cancer drug Revlimid has finally found a competitor in Israel-based Teva Pharmaceuticals’ generic version, lenalidomide.
Sanofi will more than $1 billion to build out its mRNA facilities and programs over the next several years. The site is expected to become operational in 2025.
Currently, women with breast and ovarian cancers have limited treatment options. Anixa Biosciences, ImmunoGen and IMV are working to change that.
Creyon Bio, a drug development company, has launched with more than $40 million in seed and Series A financing led by DCVC Bio and Lux Capital.
The trial’s primary endpoint was to assess endometrial health, with additional goals of evaluating the safety and tolerability of the drug.